Dr. Gina Ayala - Clinical Trials Daily

Thyroid Eye Disease, Elegrobart, Phase 3, VRDN-003

Elegrobart's Zero Hearing Loss and Subcutaneous Convenience Rewrite the Playbook for Thyroid Eye Disease

Phase 3 REVEAL-1 data establishes a differentiated safety profile for Elegrobart, utilizing an extended half-life YTE mutation and Q8W dosing to bypass the severe sensorineural hearing loss characteristic of current intravenous IGF-1R therapies. See Disclaimer below * Thyroid Eye Disease is a disfiguring, potentially blinding autoimmune condition marked by severe ocular

Glanzmann Thrombasthenia, Sutacimig, Hematology, Rare Diseases, Prophylaxis

Sutacimig in Glanzmann Thrombasthenia: From Reactive Rescue to Subcutaneous Prophylaxis

Phase 2 data from HMB-001-CL101 positions sutacimig as a viable prophylactic standard of care, with particular relevance for the alloimmunized subpopulation where current options have effectively run out. See Disclaimer below * Glanzmann Thrombasthenia (GT) is an ultra-rare autosomal recessive bleeding disorder caused by a genetic deficiency or dysfunction in the

Zasocitinib, Plaque Psoriasis, TYK2 Inhibitors, TAK-279, Dermatology

Zasocitinib: JH2 Selectivity, Phase 3 Efficacy, and the Road to Best-in-Class TYK2 Status in Plaque Psoriasis

Phase 3 LATITUDE data positions zasocitinib well above apremilast, while the pending NCT06973291 head-to-head trial against deucravacitinib will ultimately determine best-in-class standing among TYK2 inhibitors. See Disclaimer below * Plaque psoriasis affects approximately 7 million patients in the US, roughly 2.0 to 2.4 million of whom carry moderate-to-severe disease.